We successfully represented Pfizer in this patent infringement action. Seedlings – a non-practicing entity – alleged that Pfizer’s EpiPen infringed a Seedlings patent. Seedlings was seeking all of the profits earned by Pfizer on EpiPen sales since 2014. Following a three week trial, Justice Grammond agreed that the patent claims asserted by Seedlings were not infringed and were also invalid.